A detailed history of Blair William & CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 226,954 shares of VKTX stock, worth $11.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
226,954
Previous 101,207 124.25%
Holding current value
$11.7 Million
Previous $5.36 Million 167.86%
% of portfolio
0.04%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$49.84 - $70.47 $6.27 Million - $8.86 Million
125,747 Added 124.25%
226,954 $14.4 Million
Q2 2024

Aug 12, 2024

SELL
$47.39 - $80.2 $9.38 Million - $15.9 Million
-198,028 Reduced 66.18%
101,207 $5.36 Million
Q1 2024

May 09, 2024

BUY
$17.4 - $94.5 $4.19 Million - $22.8 Million
240,863 Added 412.63%
299,235 $24.5 Million
Q4 2023

Feb 12, 2024

SELL
$9.24 - $19.64 $297,278 - $631,877
-32,173 Reduced 35.53%
58,372 $1.09 Million
Q3 2023

Nov 09, 2023

SELL
$10.92 - $16.0 $287,567 - $421,344
-26,334 Reduced 22.53%
90,545 $1 Million
Q2 2023

Aug 11, 2023

BUY
$14.84 - $24.79 $132,580 - $221,473
8,934 Added 8.28%
116,879 $1.89 Million
Q1 2023

May 12, 2023

BUY
$8.08 - $17.33 $604,287 - $1.3 Million
74,788 Added 225.56%
107,945 $1.8 Million
Q4 2022

Feb 10, 2023

SELL
$2.72 - $9.4 $219,316 - $757,931
-80,631 Reduced 70.86%
33,157 $311,000
Q3 2022

Nov 09, 2022

SELL
$2.55 - $3.89 $115,081 - $175,555
-45,130 Reduced 28.4%
113,788 $310,000
Q2 2022

Aug 10, 2022

SELL
$2.11 - $3.15 $1,685 - $2,516
-799 Reduced 0.5%
158,918 $459,000
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $19,362 - $31,495
6,454 Added 4.21%
159,717 $479,000
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $37,177 - $54,311
8,082 Added 5.57%
153,263 $705,000
Q3 2021

Nov 12, 2021

SELL
$5.58 - $7.04 $64,476 - $81,347
-11,555 Reduced 7.37%
145,181 $912,000
Q2 2021

Aug 12, 2021

BUY
$5.19 - $6.73 $15,570 - $20,190
3,000 Added 1.95%
156,736 $939,000
Q1 2021

May 13, 2021

BUY
$5.74 - $9.67 $39,663 - $66,819
6,910 Added 4.71%
153,736 $972,000
Q4 2020

Feb 09, 2021

BUY
$5.3 - $6.71 $198,352 - $251,121
37,425 Added 34.21%
146,826 $827,000
Q3 2020

Nov 06, 2020

BUY
$5.73 - $8.11 $208,199 - $294,676
36,335 Added 49.73%
109,401 $637,000
Q2 2020

Aug 12, 2020

SELL
$4.35 - $8.08 $6,524 - $12,120
-1,500 Reduced 2.01%
73,066 $527,000
Q1 2020

May 11, 2020

SELL
$3.45 - $7.95 $52,629 - $121,277
-15,255 Reduced 16.98%
74,566 $349,000
Q4 2019

Feb 13, 2020

SELL
$6.38 - $8.73 $385,907 - $528,051
-60,487 Reduced 40.24%
89,821 $720,000
Q3 2019

Nov 12, 2019

SELL
$6.55 - $8.6 $53,382 - $70,090
-8,150 Reduced 5.14%
150,308 $1.03 Million
Q2 2019

Aug 13, 2019

SELL
$7.67 - $10.63 $37,007 - $51,289
-4,825 Reduced 2.95%
158,458 $1.32 Million
Q1 2019

May 14, 2019

BUY
$7.58 - $9.94 $11,013 - $14,442
1,453 Added 0.9%
163,283 $1.62 Million
Q4 2018

Feb 14, 2019

BUY
$7.16 - $16.21 $1.12 Million - $2.53 Million
156,330 Added 2842.36%
161,830 $1.24 Million
Q3 2018

Nov 13, 2018

BUY
$9.7 - $19.65 $4,850 - $9,825
500 Added 10.0%
5,500 $96,000
Q2 2018

Aug 13, 2018

BUY
$3.88 - $12.74 $19,400 - $63,700
5,000 New
5,000 $47,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.